GLP-1 receptor agonists, including semaglutide and tirzepatide, have quickly become some of the most widely prescribed medications for weight management. Their popularity has been fueled by strong demand, the rise of telehealth prescribing, and the growing availability of compounded versions. However, this same popularity has placed the drugs under heightened regulatory and legal scrutiny. Compounded GLP-1 products, which are modified versions of FDA-approved medications, carry added safety and compliance risks, and, importantly, expose providers to potential liability.
Recent Legal Developments This increased attention is already playing out in the courts. On August 4, 2025, Novo Nordisk, the manufacturer of the most widely known GLP-1 medications, filed multiple lawsuits in federal courts across the country. These lawsuits target pharmacies, medical spas, and weight-loss clinics accused of selling compounded versions of semaglutide and misrepresenting them as safe, FDA-approved alternatives.
One case of note was filed in the Southern District of New York against a New York-based company that marketed and sold compounded products purporting to contain semaglutide. Novo Nordisk alleges that the company falsely advertised its products as FDA-approved and clinically validated. The lawsuit seeks injunctive relief, corrective disclaimers, recovery of profits, and monetary damages, citing false advertising and deceptive business practices. The case underscores how aggressively manufacturers and regulators are scrutinizing the use of compounded GLP-1 medications, and the risks that healthcare providers face if compliance measures are not carefully followed.
Guidance for Providers For physicians, the safest course is to prescribe only FDA-approved GLP-1 medications unless a specific clinical need justifies the use of a compounded version. In such cases, thorough documentation is essential. This includes patient evaluations, the clinical rationale for prescribing, contraindications considered, and informed consent. Telehealth encounters require additional vigilance to ensure full compliance with HIPAA and state privacy regulations, along with secure management of patient data.
For pharmacists, diligence is equally critical. Prescriptions must be confirmed as appropriate, and compounded drugs should only be dispensed when the clinical justification is clear and documented by the prescriber. Pharmacists should also ensure that patients receive counseling that accurately communicates the safety and efficacy of FDA-approved drugs, without implying that compounded products are equivalent.
Preventing Legal Exposure The recent lawsuits make one point clear: providers who fail to adhere to best practices in prescribing and dispensing GLP-1 drugs put themselves at risk of both regulatory and civil liability. To mitigate that risk, healthcare organizations should implement strong internal policies, ensure regular staff training, and make thorough documentation a priority. Keeping up to date with FDA and state guidance on compounded medications is also essential. Ultimately, maintaining detailed records of clinical decisions and patient communications is not only a best practice – it is one of the strongest defenses should legal or regulatory scrutiny arise.
Our firm closely monitors regulatory and legal developments affecting healthcare providers, including the increased scrutiny of GLP-1 medications. We work with healthcare organizations to implement compliance policies, strengthen documentation practices, and proactively manage risks associated with prescribing and dispensing. If your organization has questions about compounded drug compliance or strategies to minimize liability exposure in connection with GLP-1 medications, please contact our healthcare attorneys at (212) 668-0200 or info@mdrxlaw.com.
